Detoxified O-Specific Polysaccharide (O-SP)–Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene

Keyphrases

• O-polysaccharide 100%
• Lipopolysaccharide 100%
• Shigella 100%
• Shigella Vaccine 100%
• Protein Conjugates 100%
• Vaccine Development 100%
• Emerging Approaches 100%
• Shigella Sonnei 66%
• Shigella Flexneri 50%
• IgG Antibody 50%
• Glycoconjugates 50%
• Israeli 16%
• Healthy Volunteers 16%
• Advanced Stage 16%
• Older Adults 16%
• Young children 16%
• Clinical Evaluation 16%
• Soldiers 16%
• Low Risk 16%
• Field Unit 16%
• Serum IgG 16%
• Conjugate Vaccine 16%
• S. Dysenteriae 16%
• Most Common Cause 16%
• Diarrheal Disease 16%
• Infection Risk 16%
• Covalently Bound 16%
• Protective Efficacy 16%
• Vaccine Strain 16%
• Low-middle Income Countries 16%
• Disease-associated 16%
• Correlates of Protection 16%
• Successful Development 16%
• Phase II Study 16%
• Moderate-to-severe Diarrhea 16%
• Haemophilus Influenzae Type b Vaccine 16%
• Young Ones 16%
• Phase I Study 16%
• Attenuated Oral Vaccine 16%
• Parenteral Delivery 16%
• Local Immune Response 16%
• Protein Carrier 16%
• U.S. National Institutes of Health 16%
• Gut mucosa 16%
• Mandatory Vaccines 16%
• Protective Immunity 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Lipopolysaccharide 100%
• Polysaccharide 100%
• Shigella 100%
• Shigella Vaccine 100%
• Vaccine Development 100%
• Immunoglobulin G 50%
• Glycoconjugate 50%
• Infection 33%
• Conjugate Vaccine 33%
• Diseases 33%
• Normal Human 16%
• Clinical Trial 16%
• Diarrhea 16%
• Dysentery 16%
• Haemophilus Influenzae Type B 16%
• Vaccine Strain 16%
• Oral Vaccine 16%